Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.
about
Smallpox vaccines for biodefense: need and feasibilityPersisting humoral antiviral immunity within the Japanese population after the discontinuation in 1976 of routine smallpox vaccinations.Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challengeEvaluating the orthopoxvirus type I interferon-binding molecule as a vaccine target in the vaccinia virus intranasal murine challenge model.Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in miceAntibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax.Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.Replicating poxviruses for human cancer therapy.Modified vaccinia virus ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression
P2860
Q22305942-D92D0B19-9BBA-4929-8F10-921E65253D06Q33736345-B2E27CB4-5B66-4F5B-BBAF-E7771E9A352BQ34092845-C64340A5-EF92-47E3-8AEB-3CE9654DF0B8Q34289866-15CCF0EF-47AE-40A2-8A79-46F4B243628FQ34502997-F567465D-0274-4019-979F-DA9EB3D924F6Q34819434-847E34E5-ADC5-4E40-90E7-3758FAA37CE5Q35844057-5593BB61-353F-4CCB-BA3E-EA13592958DAQ35947780-67BF2F91-FFD9-4E06-B188-361AA1215356Q36424513-965372A2-8EF6-4930-9203-D302226C6AA5Q36808703-0B1E61E5-5A37-442D-BBFD-8F7968474304Q38407351-9BFBD7AD-DF85-458E-A588-7B52B23A3A4CQ39897867-53DA061F-A25B-4015-8E89-18ABF1E643F2
P2860
Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Modified vaccinia virus Ankara ...... pressing murine interleukin-4.
@en
Modified vaccinia virus Ankara ...... pressing murine interleukin-4.
@nl
type
label
Modified vaccinia virus Ankara ...... pressing murine interleukin-4.
@en
Modified vaccinia virus Ankara ...... pressing murine interleukin-4.
@nl
prefLabel
Modified vaccinia virus Ankara ...... pressing murine interleukin-4.
@en
Modified vaccinia virus Ankara ...... pressing murine interleukin-4.
@nl
P2093
P2860
P1433
P1476
Modified vaccinia virus Ankara ...... pressing murine interleukin-4.
@en
P2093
John A Rutigliano
Lewis H McCurdy
Teresa R Johnson
P2860
P304
12471-12479
P356
10.1128/JVI.78.22.12471-12479.2004
P407
P577
2004-11-01T00:00:00Z